Traumatic Brain Injury Pipeline Assessment, 2023 Updates | in-Depth Insights Into the Emerging Drugs, Latest Drug Approvals, Clinical Trials, and Treatment Outlook | Neuronasal LLC, Nyrada Inc.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Traumatic Brain Injury pipeline constitutes key companies continuously working towards developing Traumatic Brain Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Traumatic Brain Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Traumatic Brain Injury Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Traumatic Brain Injury Market.


Some of the key takeaways from the Traumatic Brain Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Traumatic Brain Injury treatment therapies with a considerable amount of success over the years. 
Traumatic Brain Injury companies working in the treatment market are NeuroTrauma Sciences, ALSP Inc., AlzeCure, Odyssey Group, Pinteon Therapeutics, Vasopharm, SanBio, and others, are developing therapies for the Traumatic Brain Injury treatment 
Emerging Traumatic Brain Injury therapies in the different phases of clinical trials are- NTS-105, Research Program, ACD856, PRV 002, PNT001, VAS203, Vandefitemcel, and others are expected to have a significant impact on the Traumatic Brain Injury market in the coming years.   
In March 2022, SanBio has finished submitting an application for approval of SB623 as a treatment for chronic motor impairment following TBI with the Ministry of Health, Labour, and Welfare (MHLW) of Japan based on the STEMTRA trial findings.The MHLW and the U.S. Food and Drug Administration (FDA) both designated SB623 as an orphan regenerative medicine treatment and as an advanced therapy for regenerative medicine (RMAT), in addition to the Sakigake classification
In July 2022, The Regenerative Medicine Subcommittee meeting (lower panel of Pharmaceutical Affairs and Food Sanitation Council) will be held on August 3 according to a statement made on July 20 by Japan’s Ministry of Health, Labour, and Welfare (MHLW)


Traumatic Brain Injury Overview

Traumatic brain injury (TBI), defined by the American Association of Neurological Surgeons (2022), is a disturbance in the brain’s regular operation that can be brought on by a blow, bump, or jolt to the head, by the head violently slamming into an object, or by an object piercing the skull and entering the brain tissue.


Get a Free Sample PDF Report to know more about Traumatic Brain Injury Pipeline Therapeutic Assessment-


Emerging Traumatic Brain Injury Drugs Under Different Phases of Clinical Development Include:

NTS-105: NeuroTrauma Sciences
Research Program: ALSP Inc.
ACD856: AlzeCure
PRV 002: Odyssey Group
PNT001: Pinteon Therapeutics
VAS203: Vasopharm
Vandefitemcel: SanBio


Traumatic Brain Injury Pipeline Therapeutics Assessment

Traumatic Brain Injury Assessment by Product Type
Traumatic Brain Injury By Stage and Product Type
Traumatic Brain Injury Assessment by Route of Administration
Traumatic Brain Injury By Stage and Route of Administration
Traumatic Brain Injury Assessment by Molecule Type
Traumatic Brain Injury by Stage and Molecule Type


DelveInsight’s Traumatic Brain Injury Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further Traumatic Brain Injury product details are provided in the report. Download the Traumatic Brain Injury pipeline report to learn more about the emerging Traumatic Brain Injury therapies


Some of the key companies in the Traumatic Brain Injury Therapeutics Market include:

Key companies developing therapies for Traumatic Brain Injury are – Neuronasal LLC, Nyrada Inc, Astrocyte Pharmaceuticals Inc, Athersys Inc, Biogen Inc, Cellvation Inc, Expesicor Inc, Hillhurst Biopharmaceuticals Inc, ImmunoChem Therapeutics LLC, and Mercaptor Discoveries Inc., and others.


Traumatic Brain Injury Pipeline Analysis:

The Traumatic Brain Injury pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment.
Traumatic Brain Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Traumatic Brain Injury drugs and therapies


Traumatic Brain Injury Pipeline Market Drivers

Increase in the prevalence Brain Injuries are some of the important factors that are fueling the Traumatic Brain Injury Market.


Traumatic Brain Injury Pipeline Market Barriers

However, less Robust pipeline, side-effects associated and other factors are creating obstacles in the Traumatic Brain Injury Market growth


Scope of Traumatic Brain Injury Pipeline Drug Insight    

Coverage: Global
Key Traumatic Brain Injury Companies: NeuroTrauma Sciences, ALSP Inc., AlzeCure, Odyssey Group, Pinteon Therapeutics, Vasopharm, SanBio, and others
Key Traumatic Brain Injury Therapies: NTS-105, Research Program, ACD856, PRV 002, PNT001, VAS203, Vandefitemcel, and others
Traumatic Brain Injury Therapeutic Assessment: Traumatic Brain Injury current marketed and Traumatic Brain Injury emerging therapies
Traumatic Brain Injury Market Dynamics: Traumatic Brain Injury market drivers and Traumatic Brain Injury market barriers 


Request for Sample PDF Report for Traumatic Brain Injury Pipeline Assessment and clinical trials


Table of Contents


Traumatic Brain Injury Report Introduction


Traumatic Brain Injury Executive Summary


Traumatic Brain Injury Overview


Traumatic Brain Injury- Analytical Perspective In-depth Commercial Assessment


Traumatic Brain Injury Pipeline Therapeutics


Traumatic Brain Injury Late Stage Products (Phase II/III)


Traumatic Brain Injury Mid Stage Products (Phase II)


Traumatic Brain Injury Early Stage Products (Phase I)


Traumatic Brain Injury Preclinical Stage Products


Traumatic Brain Injury Therapeutics Assessment


Traumatic Brain Injury Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Traumatic Brain Injury Key Companies


Traumatic Brain Injury Key Products


Traumatic Brain Injury Unmet Needs


Traumatic Brain Injury Market Drivers and Barriers


Traumatic Brain Injury Future Perspectives and Conclusion


Traumatic Brain Injury Analyst Views




About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.



About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: